New combination of the old drugs for elderly patients with small-cell lung cancer: a phase II study of the PAVE regimen.

摘要: PURPOSEA regimen of cisplatin, doxorubicin, vincristine, and etoposide (PAVE) was designed for patients with small-cell lung cancer (SCLC) who were older than 65 years, the following objectives compared standard chemotherapy regimens: maintain efficacy, diminish toxicity, enhance compliance, improve administration convenience at an acceptable cost.PATIENTS AND METHODSThe PAVE consisted cisplatin 30 mg/m2 intravenously (i.v.) day 1; doxorubicin 40 i.v. vincristine 1.0 100 1 orally days 3 5. Cycles repeated every weeks four cycles. Patients limited-stage disease selected extensive-stage received thoracic irradiation delivered concurrently etoposide-cisplatin (EP) time second cycle.RESULTSSixty-six eligible treated, which included 25 41 disease. Med...